Want to see JP:4588 full AI Analyst Report?
Top Page
Oncolys BioPharma, Inc.
(4588)
Select Model
Select Model
Rating:48Neutral
Price Target:
¥5,396.00
▲(466.21% Upside)
Action:Reiterated
Date:09/09/26
The score is held down primarily by weak financial performance—multi-year revenue collapse, persistent large operating losses, and heavy ongoing cash burn. Technicals are a partial offset, with strong upside momentum and price well above key moving averages, but overbought indicators raise near-term pullback risk. Valuation remains pressured due to negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Manageable leverage
Modest leverage relative to equity gives Oncolys greater financial flexibility than a heavily indebted biotechnology company. The improvement in debt-to-equity, together with expanded equity and assets, provides capacity to support development activities and absorb volatility over the next several quarters.
Negative Factors
Revenue collapse
The multi-year revenue decline shows that current commercial or milestone-related activity has not produced a stable growth base. Revenue dropping to a small fraction of its 2022 level weakens operating scale and leaves future performance highly dependent on a major product or development inflection.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable leverage
Modest leverage relative to equity gives Oncolys greater financial flexibility than a heavily indebted biotechnology company. The improvement in debt-to-equity, together with expanded equity and assets, provides capacity to support development activities and absorb volatility over the next several quarters.
Read all positive factors
Oncolys BioPharma, Inc. (4588) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥145.67B
Dividend YieldN/A
Average Volume (3M)1.27M
Price to Earnings (P/E)―
Beta (1Y)2.11
Revenue Growth1662.38%
EPS Growth42.86%
CountryJP
Employees42
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-81.78
Shares Outstanding29,465,700
10 Day Avg. Volume1,675,650
30 Day Avg. Volume1,267,613
Financial Highlights & Ratios
PEG Ratio-4.72
Price to Book (P/B)8.90
Price to Sales (P/S)1247.26
P/FCF Ratio-18.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Oncolys BioPharma, Inc. Business Overview & Revenue Model
Company Description
Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research, development, manufacturing, sales, and distribution of oncolytic viruses, pharmaceutical drugs, and diagnostic agents for tumors across Japan, other Asian regions, and the U...
How the Company Makes Money
Detailed, company-specific revenue breakdown (e.g., product sales by drug, recurring service revenue, or disclosed milestone/royalty structures) is not available in the information provided here; therefore, this data point is null....
Oncolys BioPharma, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
21
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 28.55M | 31.38M | 63.04M | 976.18M | 642.49M |
| Gross Profit | 28.30M | 31.38M | 30.61M | 338.49M | 198.80M |
| EBITDA | -2.05B | -1.68B | -1.93B | -1.14B | -1.60B |
| Net Income | -2.06B | -1.68B | -1.94B | -1.15B | -1.62B |
Balance Sheet | |||||
| Total Assets | 4.56B | 3.20B | 2.04B | 2.65B | 4.29B |
| Cash, Cash Equivalents and Short-Term Investments | 3.72B | 2.41B | 1.53B | 1.71B | 3.45B |
| Total Debt | 320.02M | 324.64M | 315.17M | 393.66M | 503.47M |
| Total Liabilities | 555.91M | 446.65M | 566.50M | 491.69M | 697.88M |
| Stockholders Equity | 4.00B | 2.75B | 1.47B | 2.16B | 3.59B |
Cash Flow | |||||
| Free Cash Flow | -1.94B | -2.02B | -1.34B | -1.72B | -1.74B |
| Operating Cash Flow | -1.94B | -2.02B | -1.34B | -1.72B | -1.74B |
| Investing Cash Flow | -7.58M | -4.71M | -5.39M | 20.12M | -942.00K |
| Financing Cash Flow | 3.22B | 2.88B | 1.14B | -113.83M | 3.09B |
Oncolys BioPharma, Inc. Technical Analysis
Positive
953.00
Price Trends
3173.32
Positive
2951.97
Positive
2384.72
Positive
Market Momentum
516.85
Negative
75.29
Negative
82.42
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4588, the sentiment is Positive. The current price of 953 is below the 20-day moving average (MA) of 3991.00, below the 50-day MA of 3173.32, and below the 200-day MA of 2384.72, indicating a bullish trend. The MACD of 516.85 indicates Negative momentum. The RSI at 75.29 is Negative, neither overbought nor oversold. The STOCH value of 82.42 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4588.
Oncolys BioPharma, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ¥8.10B | -7.09 | ― | ― | -19.99% | 16.36% | |
50 Neutral | ¥15.18B | -11.55 | ― | ― | ― | -8.52% | |
48 Neutral | ¥145.67B | -99.16 | ― | ― | 1662.38% | 42.86% | |
48 Neutral | ¥141.32B | -38.88 | -7.17% | ― | 0.62% | 27.66% | |
45 Neutral | ¥8.98B | -9.32 | -42.79% | ― | -8.58% | 19.03% |
* General Sector Average
JP:4588
Oncolys BioPharma, Inc.
5,450.00
4,828.00
776.21%
JP:4587
Peptidream
1,096.00
-639.00
-36.83%
JP:4564
OncoTherapy Science
22.00
-4.00
-15.38%
JP:4575
CanBas Co., Ltd.
767.00
-412.00
-34.94%
JP:4583
Chiome Bioscience Inc.
97.00
-36.00
-27.07%
Oncolys BioPharma, Inc. Corporate Events
Oncolys BioPharma Surges in Sales but Keeps Forecast and Dividends on Hold
Aug 7, 2026
Oncolys BioPharma reported a sharp jump in net sales to ¥503 million for the six months ended June 30, 2026, up more than 16-fold from a year earlier, while significantly narrowing its net loss to ¥762 million and improving basic loss pe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.